Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

Open access
Horwitz, Mitchell E., Chao, Nelson J., Rizzieri, David A., Long, Gwynn D., Sullivan, Keith M., Gasparetto, Cristina, Chute, John P., Morris, Ashley, McDonald, Carolyn, Waters-Pick, Barbara, Stiff, Patrick, Wease, Steven, Peled, Amnon, Snyder, David, Cohen, Einat Galamidi, Shoham, Hadas, Landau, Efrat, Friend, Etty, Peleg, Iddo, Aschengrau, Dorit, Yackoubov, Dima, Kurtzberg, Joanne, Peled, Tony·2014·Journal of Clinical Investigation

Abstract

BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis that a UCB-derived cell product consisting of stem cells expanded for 21 days in the presence of nicotinamide and a noncultured T cell fraction (NiCord) can accelerate hematopoietic recovery and provide long-term engraftment. METHODS: In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated UCB unit. Safety, hematopoietic recovery, and donor engraftment were assessed and compared with historical controls. RESULTS: No adverse events were attributable to the infusion of NiCord. Complete or partial neutrophil and T cell engraftment derived from NiCord was observed in 8 patients, and NiCord engraftment remained stable in all patients, with a median follow-up of 21 months. Two patients achieved long-term engraftment with the unmanipulated unit. Patients transplanted with NiCord achieved earlier median neutrophil recovery (13 vs. 25 days, P < 0.001) compared with that seen in historical controls. The 1-year overall and progression-free survival rates were 82% and 73%, respectively. CONCLUSION: UCB-derived hematopoietic stem and progenitor cells expanded in the presence of nicotinamide and transplanted with a T cell-containing fraction contain both short-term and long-term repopulating cells. The results justify further study of NiCord transplantation as a single UCB graft. If long-term safety is confirmed, NiCord has the potential to broaden accessibility and reduce the toxicity of UCB transplantation. TRIAL REGISTRATION: Clinicaltrials.gov NCT01221857. FUNDING: Gamida Cell Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci74556

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 264

Metadata

Authors
Horwitz, M. E., Chao, N. J., Rizzieri, D. A., Long, G. D., Sullivan, K. M., Gasparetto, C., Chute, J. P., Morris, A., McDonald, C., Waters-Pick, B., Stiff, P., Wease, S., Peled, A., Snyder, D., Cohen, E. G., Shoham, H., Landau, E., Friend, E., Peleg, I., Aschengrau, D., Yackoubov, D., Kurtzberg, J., & Peled, T.
Venue
Journal of Clinical Investigation
Published
2014-06-09
Volume
124
Issue
7
Pages
3121-3128
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1978876757
Cited by
264
References
17
FWCI
22.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. https://app.cochat.ai/papers/10.1172/jci74556
The paper
Horwitz, M. E., Chao, N. J., Rizzieri, D. A., Long, G. D., Sullivan, K. M., Gasparetto, C., Chute, J. P., Morris, A., McDonald, C., Waters-Pick, B., Stiff, P., Wease, S., Peled, A., Snyder, D., Cohen, E. G., Shoham, H., Landau, E., Friend, E., Peleg, I., . . . Peled, T. (2014). Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. Journal of Clinical Investigation. https://doi.org/10.1172/jci74556

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.